Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma Phase I and II and Other Solid Tumors Phase I Only.
A Phase II Study of Brentuximab Vedotin in Combination with Checkpoint Inhibitor CPI Therapy in Subjects with Metastatic Solid Tumors After Progression on Prior PD-1 Inhibitor Treatment
A Randomized Phase II Study of ATR Inhibition in Advanced PD-L1-refractory Merkel Cell Carcinoma: The MATRiX Trial
Study Type: Treatment
Phase: II
NCTID: NCT05947500
Principal Investigator:
Nina Mathew
A Phase III, Randomized, Double-blind Study of Encorafenib and Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Previously Untreated BRAF V600E/K Mutation-Positive Participants with Unresectable or Metastatic Melanoma. STARBOARD
A Phase I/II, open-label study of PD-1 knockout tumor-infiltrating lymphocytes IOV-4001 in participants with unresectable or metastatic melanoma or Stage III or IV non-small-cell lung cancer
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial
A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib NSC-763760 and Trametinib NSC-763093 in BRAFV600E/K Mutant Melanoma
A Phase III Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA A02:01-Positive Participants With Previously Untreated Advanced Melanoma PRISM-MEL-301
Study Type: Treatment
Phase: III
NCTID: NCT06112314
Principal Investigator:
Gary Doolittle
Phase I/II Open-Label Study to Evaluate the Safety and Preliminary Efficacy of Mrx0518 in Combination with Pembrolizumab in Patients with Non-Small-Cell Lung Cancer, Renal Cell Carcinoma, Bladder Cancer, and Melanoma Who Have Progressed on PD-1 Inhibitors
Phase II/III Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator?s Choice in HLAA02:01-positive Participants with Previously Treated Advanced Melanoma TEBE-AM
Study Type: Treatment
Phase: II/III
NCTID: NCT05549297
Principal Investigator:
Gary Doolittle